Advertisement

Topics

LimFlow Raises €27 Million ($33.5 Million) in Series C Financing Led by Sofinnova Partners to Advance Innovative Critical Limb Ischemia (CLI) Treatment

08:00 EDT 16 Apr 2018 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
LimFlow SA, developer of innovative, peripheral endovascular technology transforming the treatment of critical limb ischemia (CLI), today announced it has secured €27 million ($33.5 million) in an oversubscribed Series ...

Other Sources for this Article

PRESS:
For LimFlow SA
Michelle McAdam, Tel: (310) 902-1274
Chronic Communications Inc.
michelle@chronic-comm.com
or
For Sofinnova Partners
Anne REIN, Tel: +33 (0)6 03 35 92 05
anne.rein@strategiesimage.com

NEXT ARTICLE

More From BioPortfolio on "LimFlow Raises €27 Million ($33.5 Million) in Series C Financing Led by Sofinnova Partners to Advance Innovative Critical Limb Ischemia (CLI) Treatment"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Healthcare
Health care (or healthcare) is the diagnosis, treatment, and prevention of disease, illness, injury, and other physical and mental impairments in humans. Health care is delivered by practitioners in medicine, chiropractic, dentistry, nursing, pharmacy, a...